GMED
Globus Medical, Inc.
Price Chart
Latest Quote
$79.53
| Previous Close | $80.91 |
| Open | $80.74 |
| Day High | $80.46 |
| Day Low | $78.77 |
| Volume | 207,453 |
Stock Information
| Shares Outstanding | 113.31M |
| Total Debt | $115.94M |
| Cash Equivalents | $629.85M |
| Revenue | $3.10B |
| Net Income | $586.71M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $10.45B |
| P/E Ratio | 17.99 |
| EPS (TTM) | $4.28 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.94B |
| Sales | $3.10B |
| Income | $586.71M |
| Book/sh | $34.88 |
| Cash/sh | $5.56 |
| Employees | 6K |
Financial Ratios
| Quick Ratio | 2.83 |
| Current Ratio | 4.56 |
| Debt/Eq | 2.45 |
| EPS Growth TTM | 64.70% |
Returns & Margins
| ROA | 8.18% |
| ROE | 13.30% |
| Gross Margin | 68.49% |
| Operating Margin | 21.32% |
| Profit Margin | 18.92% |
Ownership
| Insider Ownership | 0.73% |
| Institutional Ownership | 101.88% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.95 |
| PEG | 1.49 |
| P/S | 3.37 |
| P/B | 2.21 |
Analyst Data
| Recommendation | buy |
| Target Price | $105.75 |
Technical Indicators
| SMA20 | $79.64 |
| SMA50 | $80.01 |
| SMA200 | $82.99 |
| RSI | 37.01 |
| ATR | 4.0264 |
| Shares Float | 111.70M |
| Short Float | 6.59% |
| Short Ratio | 4.06 |
| Volatility | 0.95 |
| Rel Volume | 1.06 |
Performance History
| Week | -1.42% |
| Month | -0.67% |
| Quarter | -16.99% |
| 6 Months | -16.72% |
| YTD | -11.80% |
| Year | +36.02% |
| 3 Years | +24.92% |
| 5 Years | -4.49% |
| 10 Years | +211.49% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $77.00 | 2,270,400 |
| 2026-07-16 | $80.91 | 2,237,600 |
| 2026-07-15 | $78.56 | 1,481,100 |
| 2026-07-14 | $75.82 | 3,021,200 |
| 2026-07-13 | $79.75 | 2,351,000 |
| 2026-07-10 | $78.11 | 1,549,500 |
| 2026-07-09 | $76.64 | 2,158,300 |
| 2026-07-08 | $76.20 | 2,257,700 |
| 2026-07-07 | $78.83 | 1,514,900 |
| 2026-07-06 | $80.50 | 1,149,600 |
| 2026-07-02 | $80.12 | 1,752,500 |
| 2026-07-01 | $75.96 | 2,950,400 |
| 2026-06-30 | $79.01 | 2,418,500 |
| 2026-06-29 | $83.94 | 1,644,300 |
| 2026-06-26 | $86.25 | 2,491,000 |
| 2026-06-25 | $84.65 | 2,060,500 |
| 2026-06-24 | $82.12 | 2,084,600 |
| 2026-06-23 | $80.04 | 1,673,400 |
| 2026-06-22 | $79.19 | 2,007,900 |
| 2026-06-18 | $79.23 | 3,629,900 |
About Globus Medical, Inc.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
đ° Latest News
STAAR Surgical, Globus Medical, Integer Holdings, and Enovis Stocks Trade Down, What You Need To Know
StockStory âĸ 2026-07-17T22:49:46ZGMED Stock Surges 43.6% in a Year: What's Driving the Rally?
Zacks âĸ 2026-07-17T18:17:00ZReasons to Retain Alignment Healthcare Stock in Your Portfolio for Now
Zacks âĸ 2026-07-16T16:50:00ZGlobus Medical (GMED) Stock Still Looks Undervalued Despite A 39% Return
Simply Wall St. âĸ 2026-07-16T09:14:13ZThe Open Questions On ISRG Stock
Trefis âĸ 2026-07-15T18:33:01ZIART Stock Surges 52.1% in a Year: What's Driving the Rally?
Zacks âĸ 2026-07-15T16:05:00ZCan ISRG Defend Its Leadership as Global Competition Intensifies?
Zacks âĸ 2026-07-15T16:05:00ZReasons to Retain Abbott Stock in Your Portfolio for Now
Zacks âĸ 2026-07-15T16:05:00ZThe Paid-To-Hold Play On ISRG Stock: A 12% Income
Trefis âĸ 2026-07-14T18:06:47ZISRG Stock: What Does Its Valuation Imply?
Trefis âĸ 2026-07-14T12:52:23ZIncome Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $799,154,000 | $901,463,000 | $453,680,000 | $213,208,000 |
| Cost Of Revenue | $957,802,000 | $1,035,479,000 | $548,174,000 | $263,725,000 |
| Total Revenue | $2,938,931,000 | $2,519,355,000 | $1,568,476,000 | $1,022,843,000 |
| Operating Revenue | $2,938,931,000 | $2,519,355,000 | $1,568,476,000 | $1,022,843,000 |
| Expenses | ||||
| Total Expenses | $2,401,740,000 | $2,299,968,000 | $1,367,060,000 | $786,592,000 |
| Other Income Expense | $60,736,000 | $-94,476,000 | $-56,153,000 | $-7,465,000 |
| Other Non Operating Income Expenses | $3,413,000 | $2,205,000 | $-2,138,000 | $1,855,000 |
| Net Non Operating Interest Income Expense | $7,141,000 | $-4,189,000 | $20,130,000 | $14,233,000 |
| Total Other Finance Cost | $-7,141,000 | $4,189,000 | $-20,130,000 | $-14,233,000 |
| Operating Expense | $1,443,938,000 | $1,264,489,000 | $818,886,000 | $522,867,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Net Interest Income | $7,141,000 | $-4,189,000 | $20,130,000 | $14,233,000 |
| Normalized Income | $486,907,853 | $185,452,893 | $163,001,573 | $197,466,560 |
| Net Income From Continuing And Discontinued Operation | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Total Operating Income As Reported | $479,816,000 | $165,991,000 | $133,142,000 | $227,951,000 |
| Net Income Common Stockholders | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Net Income | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Net Income Including Noncontrolling Interests | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Net Income Continuous Operations | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Pretax Income | $605,068,000 | $120,722,000 | $165,393,000 | $243,019,000 |
| Special Income Charges | $60,329,000 | $-53,396,000 | $-68,274,000 | $-8,300,000 |
| Operating Income | $537,191,000 | $219,387,000 | $201,416,000 | $236,251,000 |
| Depreciation Amortization Depletion Income Statement | $118,194,000 | $119,373,000 | $51,032,000 | $17,735,000 |
| Depreciation And Amortization In Income Statement | $118,194,000 | $119,373,000 | $51,032,000 | $17,735,000 |
| Amortization Of Intangibles Income Statement | $118,194,000 | $119,373,000 | $51,032,000 | $17,735,000 |
| Gross Profit | $1,981,129,000 | $1,483,876,000 | $1,020,302,000 | $759,118,000 |
| Per Share | ||||
| Diluted EPS | $3.92 | $0.75 | $1.07 | $1.85 |
| Basic EPS | $3.98 | $0.76 | $1.09 | $1.89 |
| Other | ||||
| Tax Effect Of Unusual Items | $6,362,853 | $-14,212,107 | $-13,886,427 | $-2,022,440 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $756,710,000 | $569,457,000 | $400,957,000 | $313,823,000 |
| Total Unusual Items | $57,323,000 | $-96,681,000 | $-54,015,000 | $-9,320,000 |
| Total Unusual Items Excluding Goodwill | $57,323,000 | $-96,681,000 | $-54,015,000 | $-9,320,000 |
| Reconciled Depreciation | $276,842,000 | $253,389,000 | $145,526,000 | $68,252,000 |
| EBITDA (Bullshit earnings) | $814,033,000 | $472,776,000 | $346,942,000 | $304,503,000 |
| EBIT | $537,191,000 | $219,387,000 | $201,416,000 | $236,251,000 |
| Diluted Average Shares | $137,056,000 | $137,863,000 | $114,630,000 | $102,643,000 |
| Basic Average Shares | $135,215,000 | $135,726,000 | $113,087,000 | $100,469,000 |
| Diluted NI Availto Com Stockholders | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Tax Provision | $67,200,000 | $17,738,000 | $42,520,000 | $52,850,000 |
| Restructuring And Mergern Acquisition | $-60,329,000 | $53,396,000 | $68,274,000 | $5,959,000 |
| Gain On Sale Of Security | $-3,006,000 | $-43,285,000 | $14,259,000 | $-1,020,000 |
| Amortization | $118,194,000 | $119,373,000 | $51,032,000 | $17,735,000 |
| Research And Development | $147,246,000 | $163,754,000 | $124,010,000 | $73,015,000 |
| Selling General And Administration | $1,178,498,000 | $981,362,000 | $643,844,000 | $432,117,000 |
| Other Special Charges | - | $314,000 | $434,000 | $2,341,000 |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,393,153,000 | $1,949,829,000 | $1,638,816,000 | $1,585,328,000 |
| Total Assets | $5,302,761,000 | $5,251,750,000 | $5,086,083,000 | $2,076,126,000 |
| Total Non Current Assets | $3,177,150,000 | $3,074,490,000 | $3,170,709,000 | $1,092,782,000 |
| Other Non Current Assets | $78,781,000 | $75,096,000 | $78,590,000 | $37,323,000 |
| Non Current Deferred Assets | $218,215,000 | $94,200,000 | $10,685,000 | $48,845,000 |
| Non Current Deferred Taxes Assets | $218,215,000 | $94,200,000 | $10,685,000 | $48,845,000 |
| Investmentin Financial Assets | $71,819,000 | $66,134,000 | $75,428,000 | $495,852,000 |
| Goodwill And Other Intangible Assets | $2,180,097,000 | $2,227,504,000 | $2,359,143,000 | $261,045,000 |
| Other Intangible Assets | $745,064,000 | $795,117,000 | $924,603,000 | $63,574,000 |
| Current Assets | $2,125,611,000 | $2,177,260,000 | $1,915,374,000 | $983,344,000 |
| Other Current Assets | $65,426,000 | $49,640,000 | $44,580,000 | $20,997,000 |
| Inventory | $759,277,000 | $659,233,000 | $848,135,000 | $298,981,000 |
| Receivables | $743,665,000 | $578,330,000 | $504,870,000 | $217,308,000 |
| Taxes Receivable | $64,727,000 | $20,633,000 | $1,635,000 | $4,061,000 |
| Accounts Receivable | $678,938,000 | $557,697,000 | $503,235,000 | $213,247,000 |
| Allowance For Doubtful Accounts Receivable | $-33,434,000 | $-15,505,000 | $-8,934,000 | $-4,724,000 |
| Gross Accounts Receivable | $712,372,000 | $573,202,000 | $512,169,000 | $217,971,000 |
| Cash Cash Equivalents And Short Term Investments | $557,243,000 | $890,057,000 | $517,789,000 | $446,058,000 |
| Cash And Cash Equivalents | $526,156,000 | $784,438,000 | $467,292,000 | $150,466,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $118,656,000 | $537,188,000 | $520,404,000 | $6,011,000 |
| Long Term Debt And Capital Lease Obligation | $103,918,000 | $83,588,000 | $508,437,000 | $3,475,000 |
| Current Debt And Capital Lease Obligation | $14,738,000 | $453,600,000 | $11,967,000 | $2,536,000 |
| Current Debt | - | $443,351,000 | - | - |
| Other Current Borrowings | - | $443,351,000 | - | - |
| Long Term Debt | - | - | $417,400,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $729,511,000 | $1,074,417,000 | $1,088,124,000 | $229,753,000 |
| Total Non Current Liabilities Net Minority Interest | $231,012,000 | $218,504,000 | $695,777,000 | $70,549,000 |
| Other Non Current Liabilities | $103,338,000 | $111,027,000 | $102,919,000 | $65,295,000 |
| Non Current Deferred Liabilities | $23,756,000 | $23,889,000 | $84,421,000 | $1,779,000 |
| Non Current Deferred Taxes Liabilities | $23,756,000 | $23,889,000 | $84,421,000 | $1,779,000 |
| Current Liabilities | $498,499,000 | $855,913,000 | $392,347,000 | $159,204,000 |
| Other Current Liabilities | $19,513,000 | $33,739,000 | $61,035,000 | $13,308,000 |
| Current Deferred Liabilities | $27,655,000 | $22,140,000 | $18,369,000 | $14,100,000 |
| Payables And Accrued Expenses | $269,488,000 | $194,615,000 | $160,159,000 | $75,908,000 |
| Payables | $132,247,000 | $119,931,000 | $84,242,000 | $47,120,000 |
| Total Tax Payable | $33,395,000 | $44,813,000 | $27,571,000 | $11,019,000 |
| Income Tax Payable | $4,155,000 | $10,725,000 | $3,845,000 | $990,000 |
| Accounts Payable | $98,852,000 | $75,118,000 | $56,671,000 | $36,101,000 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $4,573,250,000 | $4,177,333,000 | $3,997,959,000 | $1,846,373,000 |
| Total Equity Gross Minority Interest | $4,573,250,000 | $4,177,333,000 | $3,997,959,000 | $1,846,373,000 |
| Stockholders Equity | $4,573,250,000 | $4,177,333,000 | $3,997,959,000 | $1,846,373,000 |
| Gains Losses Not Affecting Retained Earnings | $15,346,000 | $-6,861,000 | $-10,192,000 | $-24,630,000 |
| Other Equity Adjustments | $15,346,000 | $-6,861,000 | $-10,192,000 | $-24,630,000 |
| Retained Earnings | $1,387,957,000 | $1,152,813,000 | $1,137,266,000 | $1,239,951,000 |
| Other | ||||
| Ordinary Shares Number | $112,625,126 | $137,420,316 | $136,335,662 | $100,192,379 |
| Share Issued | $112,625,126 | $137,420,316 | $136,335,662 | $100,192,379 |
| Tangible Book Value | $2,393,153,000 | $1,949,829,000 | $1,638,816,000 | $1,585,328,000 |
| Invested Capital | $4,573,250,000 | $4,620,684,000 | $4,415,359,000 | $1,846,373,000 |
| Working Capital | $1,627,112,000 | $1,321,347,000 | $1,523,027,000 | $824,140,000 |
| Capital Lease Obligations | $118,656,000 | $93,837,000 | $103,004,000 | $6,011,000 |
| Total Capitalization | $4,573,250,000 | $4,177,333,000 | $4,415,359,000 | $1,846,373,000 |
| Additional Paid In Capital | $3,169,812,000 | $3,031,244,000 | $2,870,749,000 | $630,952,000 |
| Capital Stock | $135,000 | $137,000 | $136,000 | $100,000 |
| Common Stock | $135,000 | $137,000 | $136,000 | $100,000 |
| Long Term Capital Lease Obligation | $103,918,000 | $83,588,000 | $91,037,000 | $3,475,000 |
| Current Deferred Revenue | $27,655,000 | $22,140,000 | $18,369,000 | $14,100,000 |
| Current Capital Lease Obligation | $14,738,000 | $10,249,000 | $11,967,000 | $2,536,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $167,105,000 | $151,819,000 | $140,817,000 | $53,352,000 |
| Current Accrued Expenses | $137,241,000 | $74,684,000 | $75,917,000 | $28,788,000 |
| Investments And Advances | $71,819,000 | $66,134,000 | $75,428,000 | $495,852,000 |
| Held To Maturity Securities | $36,855,000 | - | - | - |
| Available For Sale Securities | $34,964,000 | - | - | - |
| Goodwill | $1,435,033,000 | $1,432,387,000 | $1,434,540,000 | $197,471,000 |
| Net PPE | $628,238,000 | $611,556,000 | $646,863,000 | $249,717,000 |
| Accumulated Depreciation | $-705,000,000 | $-545,786,000 | $-425,695,000 | $-343,036,000 |
| Gross PPE | $1,333,238,000 | $1,157,342,000 | $1,072,558,000 | $592,753,000 |
| Other Properties | $1,194,816,000 | $1,047,483,000 | $960,361,000 | $532,966,000 |
| Buildings And Improvements | $127,573,000 | $100,128,000 | $102,449,000 | $51,510,000 |
| Land And Improvements | $10,849,000 | $9,731,000 | $9,748,000 | $8,277,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $532,568,000 | $491,474,000 | $707,465,000 | $219,958,000 |
| Work In Process | $64,462,000 | $45,775,000 | $37,321,000 | $18,699,000 |
| Raw Materials | $162,247,000 | $121,984,000 | $103,349,000 | $60,324,000 |
| Other Short Term Investments | $31,087,000 | $105,619,000 | $50,497,000 | $295,592,000 |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $579,022,000 | $405,209,000 | $165,225,000 | $104,421,000 |
| Operating Activities | ||||
| Operating Cash Flow | $753,447,000 | $520,638,000 | $243,499,000 | $178,468,000 |
| Cash Flow From Continuing Operating Activities | $753,447,000 | $520,638,000 | $243,499,000 | $178,468,000 |
| Operating Gains Losses | $-66,000 | $30,764,000 | $-12,133,000 | $299,000 |
| Investing Activities | ||||
| Capital Expenditure | $-174,425,000 | $-115,429,000 | $-78,274,000 | $-74,047,000 |
| Investing Cash Flow | $-355,014,000 | $-176,051,000 | $302,968,000 | $-110,362,000 |
| Cash Flow From Continuing Investing Activities | $-355,014,000 | $-176,051,000 | $302,968,000 | $-110,362,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-300,451,000 | $-85,787,000 | $-225,562,000 | $-144,493,000 |
| Financing Cash Flow | $-679,160,000 | $-27,696,000 | $-231,821,000 | $-109,962,000 |
| Cash Flow From Continuing Financing Activities | $-679,160,000 | $-27,696,000 | $-231,821,000 | $-109,962,000 |
| Net Other Financing Charges | $-18,481,000 | $-52,348,000 | $-18,656,000 | $-7,185,000 |
| Net Common Stock Issuance | $-300,451,000 | $-85,787,000 | $-225,562,000 | $-144,493,000 |
| Issuance Of Capital Stock | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-449,985,000 | $0 | $0 | - |
| Income Tax Paid Supplemental Data | $98,916,000 | $158,508,000 | $100,593,000 | $77,823,000 |
| End Cash Position | $526,156,000 | $784,438,000 | $467,292,000 | $150,466,000 |
| Beginning Cash Position | $784,438,000 | $467,292,000 | $150,466,000 | $193,069,000 |
| Effect Of Exchange Rate Changes | $22,445,000 | $255,000 | $2,180,000 | $-747,000 |
| Changes In Cash | $-280,727,000 | $316,891,000 | $314,646,000 | $-41,856,000 |
| Proceeds From Stock Option Exercised | $89,757,000 | $110,439,000 | $12,397,000 | $41,716,000 |
| Common Stock Payments | $-300,451,000 | $-85,787,000 | $-225,562,000 | $-144,493,000 |
| Net Issuance Payments Of Debt | $-449,985,000 | $0 | $0 | - |
| Net Short Term Debt Issuance | $-449,985,000 | $0 | $0 | - |
| Short Term Debt Payments | $-449,985,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $71,957,000 | $-42,987,000 | $677,270,000 | $-4,880,000 |
| Sale Of Investment | $179,488,000 | $70,517,000 | $777,913,000 | $414,654,000 |
| Purchase Of Investment | $-107,531,000 | $-113,504,000 | $-100,643,000 | $-419,534,000 |
| Net Business Purchase And Sale | $-252,546,000 | $-17,635,000 | $-296,028,000 | $-31,435,000 |
| Purchase Of Business | $-252,546,000 | $-17,635,000 | $-296,028,000 | $-31,435,000 |
| Net Intangibles Purchase And Sale | $-9,746,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-9,746,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-164,679,000 | $-115,429,000 | $-78,274,000 | $-74,047,000 |
| Purchase Of PPE | $-164,679,000 | $-115,429,000 | $-78,274,000 | $-74,047,000 |
| Change In Working Capital | $-66,795,000 | $-97,554,000 | $-116,598,000 | $-105,262,000 |
| Change In Other Working Capital | $-50,851,000 | $-13,377,000 | $-408,000 | $-2,887,000 |
| Change In Payables And Accrued Expense | $42,704,000 | $22,686,000 | $2,904,000 | $20,505,000 |
| Change In Accrued Expense | $34,217,000 | $5,023,000 | $17,127,000 | $6,087,000 |
| Change In Payable | $8,487,000 | $17,663,000 | $-14,223,000 | $14,418,000 |
| Change In Account Payable | $8,487,000 | $17,663,000 | $-14,223,000 | $14,418,000 |
| Change In Prepaid Assets | $11,132,000 | $1,059,000 | $1,148,000 | $-10,292,000 |
| Change In Inventory | $-17,598,000 | $-29,860,000 | $-70,328,000 | $-61,745,000 |
| Change In Receivables | $-52,182,000 | $-78,062,000 | $-49,914,000 | $-50,843,000 |
| Changes In Account Receivables | $-52,182,000 | $-78,062,000 | $-49,914,000 | $-50,843,000 |
| Other Non Cash Items | $-95,148,000 | $262,421,000 | $94,261,000 | $2,635,000 |
| Stock Based Compensation | $49,779,000 | $54,191,000 | $52,742,000 | $32,810,000 |
| Provisionand Write Offof Assets | $32,342,000 | $40,345,000 | $14,617,000 | $6,399,000 |
| Deferred Tax | $18,625,000 | $-125,902,000 | $-57,789,000 | $-22,223,000 |
| Deferred Income Tax | $18,625,000 | $-125,902,000 | $-57,789,000 | $-22,223,000 |
| Depreciation Amortization Depletion | $276,842,000 | $253,389,000 | $145,526,000 | $68,252,000 |
| Depreciation And Amortization | $276,842,000 | $253,389,000 | $145,526,000 | $68,252,000 |
| Net Foreign Currency Exchange Gain Loss | $-12,591,000 | $25,212,000 | $-13,674,000 | $0 |
| Net Income From Continuing Operations | $537,868,000 | $102,984,000 | $122,873,000 | $190,169,000 |
| Amortization Of Securities | - | $-635,000 | $793,000 | $5,389,000 |
| Asset Impairment Charge | - | - | - | $6,400,000 |